l-dopa patch isn't possible, l-dopa doesn't pass thru the skin well plus it would have to deliver a lot of l-dopa compared to an agonist like neupro. you still need carbidopa even if you bypass the stomach and small intestine since the blood still circulates thru every cell in the body. the gel used in the duodopa pump contains carbidopa.
http://www.abbvie.ca/content/dam/abb...DOPA_PM_EN.pdf

neuoderm tried a patch, it failed, now developing a insulin pump like device to subcutaneously deliver l-dopa, not sure if their gel has carbidopa or you take it orally.
https://www.michaeljfox.org/foundati...p?grant_id=225

agonists were developed because of this problem with l-dopa breaking down outside and inside the brain , some medical professionals think we need a better agonist and there are already 3 once a day products, mirapex-xr, requip-xr and neupro.

[QUOTE=soccertese;1105565]l-dopa patch isn't possible, l-dopa doesn't pass thru the skin well plus it would have to deliver a lot of l-dopa compared to an agonist like neupro. you still need carbidopa even if you bypass the stomach and small intestine since the blood still circulates thru every cell in the body. the gel used in the duodopa pump contains carbidopa.
[url]
neuoderm tried a patch, it failed, now developing a insulin pump like device to subcutaneously deliver l-dopa, not sure if their gel has carbidopa or you take it orally.
https://www.michaeljfox.org/foundati...p?grant_id=225

QUOTE]

You beat me to the response, ST. NeuroDerm is using a liquid formulation of LD/CD in their belt pump. They tried eliminating carbidopa but it didn't work. As an aside, they will be releasing their top line Phase 2 trial results for the ND0612 pumps later today.

There is a small company, SynAgile, that is also testing an insulin-like pump for PD. They are not combining their drug with carbidopa. SynAgile is developing DopaFuse, a therapy to continuously infuse a dopamine prodrug. DopaFuse contains a novel, highly soluble L-DOPA prodrug that enables a daily dose of L-DOPA to be delivered in a small volume. Upon infusion the prodrug is broken down into L-DOPA, which is absorbed into the patient's plasma. Studies demonstrate promptly increased plasma L-DOPA after infusion of the prodrug into PD patients. Large clinical trials have already demonstrated the safety and efficacy of the prodrug in oral form. SynAgile is reformulating the prodrug so that it can be continuously infused.

I saw a presentation from SynAgile last year but haven't heard much about them recently.

[QUOTE=Tupelo3;1105590]i assume carbidopa is taken orally?